Melatonin ameliorates low-grade inflammation and oxidative stress in young Zucker diabetic fatty rats

Journal of Pineal Research

Volumn 54, Issue 4, 2013, Pages 381-388

  Agil, Ahmad ^a   Reiter, Russel J ^b   Jiménez Aranda, Aroa ^a   Ibán Arias, Ruth ^a   Navarro Alarcón, Miguel ^a   Marchal, Juan Antonio ^a   Adem, Abdu ^c   Fernández Vázquez, Gumersindo ^d  

^a UNIVERSITY OF GRANADA   (Spain)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^c UNITED ARAB EMIRATES UNIVERSITY   (United Arab Emirates)

^d HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

Low grade inflammation; Melatonin; Oxidative stress; Zucker diabetic fatty rats

Indexed keywords

C REACTIVE PROTEIN; INTERLEUKIN 6; MALONALDEHYDE; MELATONIN; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; INFLAMMATION; LIPID PEROXIDATION; MALE; NONHUMAN; OXIDATIVE STRESS; PROTEIN BLOOD LEVEL; RAT; ZUCKER DIABETIC FATTY RAT;

LOW-GRADE INFLAMMATION; MELATONIN; OXIDATIVE STRESS; ZUCKER DIABETIC FATTY RATS;

ANIMALS; DIABETES MELLITUS, EXPERIMENTAL; INFLAMMATION; MALE; MELATONIN; OXIDATIVE STRESS; RATS; RATS, ZUCKER;

EID: 84879459393     PISSN: 07423098     EISSN: 1600079X     Source Type: Journal    
DOI: 10.1111/jpi.12012     Document Type: Article

References (66)

1. BALKAU B, DEANFIELD JE, DESPRES JP et al. International Day for the Evaluation of Abdominal Obesity (IDEA): a study of waist circumference, cardiovascular disease, and diabetes mellitus in 168,000 primary care patients in 63 countries. Circulation 2007; 116:1942-1951.
2. CALI AM, CAPRIO S. Obesity in children adolescents. J Clin Endocrinol Metab 2008; 93:S31-S36.
3. KELISHADI R. Childhood overweight, obesity, and the metabolic syndrome in developing countries. Epidemiol Rev 2007; 29:62-76.
4. SZOKE E, GERICH JE. Role of impaired insulin secretion and insulin resistance in the pathogenesis of type 2 diabetes mellitus. Compr Ther 2005; 31:106-112.
5. HUMMASTI S, HOTAMISLIGIL GS. Endoplasmic reticulum stress and inflammation in obesity and diabetes. Circ Res 2010; 107:579-591.
6. BASHAN N, KOVSAN J, KACHKO I et al. Positive and negative regulation of insulin signaling by reactive oxygen and nitrogen species. Physiol Rev 2009; 89:27-71.
7. BADAWI A, KLIP A, HADDAH P et al. Type 2 diabetes mellitus and inflammation: prospects for biomarkers of risk and nutritional intervention. Diabetes Metab Syndr Obes 2010; 3:173-186.
8. PITOCCO D, ZACCARDI F, DI ESTASIO E et al. Oxidative stress, nitric oxide and diabetes. Rev Diabet Stud 2010; 7:15-25.
9. RASOULIN, KERN PA. Adipocytokines and the metabolic complications of obesity. J Clin Endocrinol Metab 2008; 93: S64-S73.
10. LIN Y, SUN Z. Current views on type 2 diabetes. J Endocrinol 2010; 204:1-11.
11. DONATH MY, BONI-SCHNETZLER M, ELLINGSGAARD H et al. Islet inflammation impairs the pancreatic beta-cell in type 2 diabetes. Physiology (Bethesda) 2009; 24:325-331.
12. FONSECA SG, BURCIN M, GROMADA J et al. Endoplasmic reticulum stress in beta-cells and development of diabetes. Curr Opin Pharmacol 2009; 9:763-770.
13. ROBERTSON RP. Beta-cell deterioration during diabetes: what's in the gun? Trends Endocrinol Metab 2009; 20:388-393.
14. REITER RJ. Pineal melatonin: cell biology of its synthesis and of its physiological interactions. Endocr Rev 1991; 12:151-180.
15. STEFULJ J, HORTNER M, GHOSH M et al. Gene expression of the key enzymes of melatonin synthesis in extrapineal tissues of the rat. J Pineal Res 2001; 30:243-247.
16. HARDELAND R, MADRID JA, TAN DX et al. Melatonin, the circadian multioscillator system and health: the need for detailed analysis of peripheral melatonin signaling. J Pineal Res 2012; 52:139-166.
17. TAN DX, MANCHESTER LC, FUENTES-BROTO L et al. Significance and application of melatonin in the regulation of brown adipose tissue metabolism: relation to human obesity. Obes Rev 2011; 12:167-188.
18. PARADIES G, PETROSILLO G, PARADIES V et al. Melatonin, cardiolipin and mitochondrial bioenergetics in health and disease. J Pineal Res 2010; 48:297-310.
19. MAYO JC, SAINZ RM, TAN DX et al. Anti-inflammatory actions of melatonin and its metabolites, N1-acetyl-N2-formyl-5-methoxykynuramine (AFMK) and N1-acetyl-5-methoxykynuramine (AMK), in macrophages. J Neuroimmunol 2005; 165:139-149.
20. CARRILLO-VICO A, GUERRERO JM, LARDONE PJ et al. A review of the multiple actions of melatonin on the immune system. Endocrine 2005; 27:189-200.
21. RADOGNA F, DIEDERICH M, GHIBELLI L. Melatonin: a pleiotropic molecule regulating inflammation. Biochem Pharmacol 2010; 80:1844-1852.
22. TAN DX, CHEN L, POEGGELER B et al. Melatonin: a potent, endogenous hydroxyl radical scavenger. J Pineal Res 1993; 1:57-60.
23. HARDELAND R, TAN DX, REITER RJ. Kynuramines, metabolites of melatonin and other indoles: the resurrection of an almost forgotten class of biogenic amines. J Pineal Res 2009; 47:109-126.
24. SCHAEFER M, HARDELAND R. The melatonin metabolite N-acetyl-5- methoxykynuramine is a potent singlet oxygen scavenger. J Pineal Res 2009; 46:49-52.
25. KORKMAZ A, REITER RJ, TOPAL T et al. Melatonin; an established antixoidant worthy of use in clinical trial. Mol Med 2009; 15:43-50.
26. REITER RJ, PAREDES SD, MANCHESTER LC et al. Reducing oxidative/ nitrosative stress: a newly-discovered genre for melatonin. Crit Rev Biochem Mol Biol 2009; 44:175-200.
27. BONNEFONT-ROUSSELOT D, COLLIN F, JORE D et al. Reaction mechanism of melatonin oxidation by reactive oxygen species in vitro. J Pineal Res 2011; 50:328-335.
28. GALANO A, TAN DX, REITER RJ. Melatonin as a natural ally against oxidative stress: a physicochemical examination. J Pineal Res 2011; 51:1-16.
29. RASMUSSEN DD, BOLDT BM, WILKINSON CW et al. Daily melatonin administration at middle age suppresses male rat visceral fat, plasma leptin, and plasma insulin to youthful levels. Endocrinology 1999; 140:1009-1012.
30. RIOS-LUGO MJ, CANO P, JIMENEZ-ORTEGA V et al. Melatonin effect on plasma adiponectin, leptin, insulin, glucose, triglycerides and cholesterol in normal and high fat-fed rats. J Pineal Res 2010; 49:342-348.
31. NDUHIRABANDI F, DU TOIT EF, BLACKHURST D et al. Chronic melatonin consumption prevents obesity-related metabolic abnormalities and protects the heart against myocardial ischemia and reperfusion injury in a prediabetic model of dietinduced obesity. J Pineal Res 2011; 50:171-182.
32. AGIL A, NAVARRO-ALARCON M, RUIZ R et al. Beneficial effects of melatonin on obesity and lipid profile in young Zucker diabetic fatty rats. J Pineal Res 2011; 50:207-212.
33. AGIL A, ROSADO I, RUIZ R et al. Melatonin improves glucose homeostasis in young Zucker diabetic fatty rats. J Pineal Res 2011; 52:203-210.
34. NEGI G, KUMAR A, SHARMA S. Melatonin modulates neuroinflammation and oxidative stress in experimental diabetic neuropathy: effects on NF-kB and Nrf2 cascades. J Pineal Res 2011; 50:124-131.
35. NEGI G, KUMAR A, KAUNDAL RK et al. Functional and biochemical evidence indicating beneficial effect of melatonin and nicotinamide alone and in combination in experimental diabetic neuropathy. Neuropharmacology 2010; 58:585-592.
36. PETERSON R, SHAW W, NEEL M et al. Zucker diabetic fatty rat as a model for non-insulin-dependent diabetes mellitus. Inst Lab Anim Resources News 1990; 32:16-27.
37. KASISKE BL, O'DONNELL MP, KEANE WF. The Zucker rat model of obesity, insulin resistance, hyperlipidemia, and renal injury. Hypertension 1992; 19:110-115.
38. SHAFRIR E. Animal models of non-insulin-dependent diabetes. Diabetes Metab Rev 1992; 8:179-208.
39. ALEIXANDRE DE ARTINANO A, MIGUEL CASTRO M. Experimental rat models to study the metabolic syndrome. Br J Nutr 2009; 102:1246-1253.
40. FERREIRA L, TEIXEIRA-DE-LEMOS E, PINTO F et al. Effects of sitagliptin treatment on dysmetabolism, inflammation, and oxidative stress in an animal model of type 2 diabetes (ZDF rat). Mediators Inflamm 2010; 2010: 592760.
41. 2-terminal kinase and serine phosphorilation of IRS-1 in the liver of ZDF rats. Am J Physiol Endocrinol Metab 2010; 298:E671-E682.
42. GOLDBERG RB. Cytokine and cytokine-like inflammation markers, endothelial dysfunction, and imbalanced coagulation in development of diabetes and its complications. J Clin Endocrinol Metab 2009; 94:3171-3182.
43. BLACK S, KUSHNER I, SAMOLS D. C-reactive protein. J Biol Chem 2004; 279:48487-48490.
44. DEVARAJ S, SINGH U, JIALAL I. Human C-reactive protein and the metabolic syndrome. Curr Opin Lipidol 2009; 20:182-189.
45. AGIL A, FULLER CJ, JIALAL I. Susceptibility of plasma to ferrous iron/hydrogen peroxide-mediated oxidation: Demonstration of a possible fenton reaction. Clin Chem 1995; 41:220-225.
46. YAGI K. Assay for blood plasma or serum. Methods Enzymol 1984; 105:328-331.
47. GREGOR MF, HOTAMISLIGIL GS. Inflammatory mechanisms in obesity. Annu Rev Immunol 2011; 29:415-445.
48. FONTANA L, EAGON JC, TRUJILLO ME et al. Visceral fat adipokine secretion is associated with systemic inflammation in obese humans. Diabetes 2007; 56:1010-1013.
49. GUSTAFSON B. Adipose tissue, inflammation and atherosclerosis. J Atheroscler Thromb 2010; 17:332-341.
50. TEIXEIRA DE LEMOS E, REIS F, BAPTISTA S et al. Exercise training decreases proinflammatory profile in Zucker diabetic (type 2) fatty rats. Nutrition 2009; 25:330-339.
51. CORNIER MA, DABELEA D, HERNANDEZ TL et al. The metabolic syndrome. Endocr Rev 2008; 29:777-822.
52. CARRILLO-VICO A, LARDONE PJ, NAJI L et al. Beneficial pleiotropic actions of melatonin in an experimental model of septic shock in mice: regulation of pro-/anti-inflammatory cytokine network, protection against oxidative damage and antiapoptotic effects. J Pineal Res 2005; 39:400-408.
53. GITTO E, KABOWNIK M, REITER RJ et al. Effects of melatonin treatment in septic newborn. Pediatr Res 2001; 50:756-760.
54. VENEROSO C, TUÑÓN MJ, GONZÁLEZ-GALLEGO J. Melatonin reduces cardiac inflammatory injury induced by acute exercise. J Pineal Res 2009; 47:184-191.
55. OCHOA JJ, DIAZ-CASTRO J, JAJARABILLE N et al. Melatonin supplementation ameliorates oxidative stress and inflammatory signaling induced by strenuous exercise in adult human males. J Pineal Res 2011; 51:373-380.
56. NICKLAS BJ, YOU T, PAHOR M. Behavioral treatments for chronic systemic inflammation: effects of dietary weight loss and exercise training. CMAJ 2005; 172:1199-1209.
57. EVANS JL, GOLDFINE ID, MADDUX BA et al. Are oxidative stress-activated signaling pathways mediators of insulin resistance and beta-cell dysfunction. Diabetes 2003; 52:1-8.
58. BAYNES JW, THORPE SR. Role of oxidative stress in diabetic complications: a new perspective on an old paradigm. Diabetes 1999; 48:1-9.
59. RODRIGUEZ C, MAYO JC, SAINZ RM et al. Regulation of antioxidant enzymes: a significant role for melatonin. J Pineal Res 2004; 36:1-9.
60. TAN DX, MANCHESTER LC, TERRON MP et al. One molecule, many derivatives: a never-ending interaction of melatonin with reactive oxygen and nitrogen species? J Pineal Res 2007; 42:28-42.
61. VENEGAS C, GARCIA JA, ESCAMES G et al. Extrapineal melatonin: Analysis of its subcellular distribución and daily fluctuations. J Pineal Res 2012; 52:217-227.
62. NAKANISHI S, YAMANE K, KAMEI N et al. A protective effect of adiponectin against oxidative stress in japanese americans: The association between adiponectin or leptin and urinary isoprostane. Metabolism 2005; 54:194-199.
63. SHAH PK, KAUL S, NILSSON J et al. Exploiting the vascular protective effects of high density lipoprotein and its apolipoproteins: an idea whose time for testing is coming, part I. Circulation 2001; 104: 2376-2383.
64. SANCHEZ-BARCELO EJ, MEDIAVILLA MD, TAN DX et al. Clinical uses of melatonin: evaluation of human trials. Curr Med Chem 2010; 17: 2070-2095.
65. CARDINALI DP, CANO P, JIMENEZ-ORTEGA V et al. Melatonin and the metabolic syndrome: physiopathologic and therapeutical implications. Neuroendocrinology 2011; 93:133-142.
66. NDUHIRABANDI F, DU TOIT EF, LOCHNER A. Melatonin and the metabolic syndrome: a tool for effective therapy in obesity-associated abnormalities? Acta Physiol (Oxf) 2012; 205:209-223.